

Supplemental Material

Table S1. Diagnostic and Therapeutic Evaluations Among Patients with STEMI by Time Period.

	Admission Prior to June 1, 2020	Admission June 1, 2020, or later
<i>Diagnostic and Therapeutic Evaluations</i>	STEMI (N=37)	STEMI (N=17)
<i>Diagnostic Evaluations</i>		
Transthoracic Echocardiography	23 (62.2)	17 (100.0)
LVEF (%), median, (25th-75th)	42.5 (35.0-57.0)	47.0 (40.0-55.0)
Coronary Angiography	15 (40.5)	12 (70.6)
CCTA	0 (0.0)	0 (0.0)
Invasive	15 (100.0)	12 (100.0)
<i>Angiographic Findings (n=27)</i>		
# Vessels with >50% stenosis		
0	3 (20.0)	0 (0.0)
1	2 (13.3)	6 (50.0)
2	4 (26.7)	3 (25.0)
>=3	5 (33.3)	3 (25.0)
Left Main Coronary Disease	1 (6.7)	0 (0.0)
<i>STEMI Reperfusion</i>		
Primary PCI	9 (24.3)	12 (70.6)
Fibrinolytic Therapy	3 (8.1)	3 (17.7)
No Reperfusion	25 (67.6)	2 (11.7)

25th, 75th = 25th and 75th quartiles; LVEF = left ventricular ejection fraction; CCTA = Coronary Computed Tomography Angiography; PCI = Percutaneous Coronary Intervention

Table S2. Multivariate Associations of STEMI Status and In-Hospital Mortality Among Patients Hospitalized with COVID-19.

	Adjusted OR (95% CI)	P-Value
Model 1*	3.14 (1.80-5.63)	<0.001
Model 2^	2.95 (1.59-5.49)	<0.001

* Adjusted for age and sex

^ Adjusted for age, sex, history of coronary artery disease, heart failure, chronic kidney disease, diabetes, pulmonary disease, immune disorder, pulmonary embolism/deep venous thrombosis, and obesity